• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纵向可溶性标志物谱揭示了 COVID-19 疾病中巨噬细胞激活引起的细胞因子风暴与疾病严重程度之间的强烈关联。

Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease.

机构信息

Department of Infectious Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Sci Rep. 2024 Jun 5;14(1):12882. doi: 10.1038/s41598-024-63586-8.

DOI:10.1038/s41598-024-63586-8
PMID:38839796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11153563/
Abstract

SARS-CoV2 infection results in a range of disease severities, but the underlying differential pathogenesis is still not completely understood. At presentation it remains difficult to estimate and predict severity, in particular, identify individuals at greatest risk of progression towards the most severe disease-states. Here we used advanced models with circulating serum analytes as variables in combination with daily assessment of disease severity using the SCODA-score, not only at single time points but also during the course of disease, to correlate analyte levels and disease severity. We identified a remarkably strong pro-inflammatory cytokine/chemokine profile with high levels for sCD163, CCL20, HGF, CHintinase3like1 and Pentraxin3 in serum which correlated with COVID-19 disease severity and overall outcome. Although precise analyte levels differed, resulting biomarker profiles were highly similar at early and late disease stages, and even during convalescence similar biomarkers were elevated and further included CXCL3, CXCL6 and Osteopontin. Taken together, strong pro-inflammatory marker profiles were identified in patients with COVID-19 disease which correlated with overall outcome and disease severity.

摘要

SARS-CoV2 感染导致一系列疾病严重程度,但潜在的差异发病机制仍不完全清楚。目前仍然难以估计和预测严重程度,特别是识别最有可能向最严重疾病状态进展的个体。在这里,我们使用了先进的模型,将循环血清分析物作为变量,并结合使用 SCODA 评分对疾病严重程度进行每日评估,不仅在单个时间点,而且在疾病过程中进行评估,以关联分析物水平和疾病严重程度。我们发现了一种非常强烈的促炎细胞因子/趋化因子谱,血清中 sCD163、CCL20、HGF、CHintinase3like1 和 Pentraxin3 的水平很高,与 COVID-19 疾病严重程度和总体预后相关。尽管分析物水平存在差异,但早期和晚期疾病阶段的生物标志物谱非常相似,甚至在康复期间,也会升高类似的生物标志物,进一步包括 CXCL3、CXCL6 和骨桥蛋白。总之,在 COVID-19 疾病患者中发现了强烈的促炎标志物谱,与总体预后和疾病严重程度相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/beae6bc2ad85/41598_2024_63586_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/307ed50f9528/41598_2024_63586_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/d12ab2687671/41598_2024_63586_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/6dd6681bf52a/41598_2024_63586_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/a5ef35fbede4/41598_2024_63586_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/beae6bc2ad85/41598_2024_63586_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/307ed50f9528/41598_2024_63586_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/d12ab2687671/41598_2024_63586_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/6dd6681bf52a/41598_2024_63586_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/a5ef35fbede4/41598_2024_63586_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2d/11153563/beae6bc2ad85/41598_2024_63586_Fig5_HTML.jpg

相似文献

1
Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease.纵向可溶性标志物谱揭示了 COVID-19 疾病中巨噬细胞激活引起的细胞因子风暴与疾病严重程度之间的强烈关联。
Sci Rep. 2024 Jun 5;14(1):12882. doi: 10.1038/s41598-024-63586-8.
2
Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.在细胞因子释放综合征背景下 SARS-CoV-2 感染的诊断。
Expert Rev Mol Diagn. 2020 Nov;20(11):1087-1097. doi: 10.1080/14737159.2020.1830760. Epub 2020 Oct 12.
3
Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.COVID-19 住院患者免疫调节前后的细胞因子谱。
J Clin Immunol. 2021 May;41(4):738-747. doi: 10.1007/s10875-020-00949-6. Epub 2021 Jan 18.
4
Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19.轻度至危重新冠肺炎患者的纵向细胞因子特征。
Front Immunol. 2021 Dec 6;12:763292. doi: 10.3389/fimmu.2021.763292. eCollection 2021.
5
Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.伊朗 COVID-19 患者的细胞因子分析;与临床严重程度的关联。
Iran J Immunol. 2021 Mar;18(1):54-64. doi: 10.22034/iji.2021.87630.1810.
6
Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.基本预测 COVID-19 患者细胞因子风暴的风险因素。
Front Immunol. 2021 Nov 10;12:745515. doi: 10.3389/fimmu.2021.745515. eCollection 2021.
7
Cytokine and chemokine profiles in the sera of COVID-19 patients with different stages of severity.COVID-19 患者不同严重程度血清中的细胞因子和趋化因子谱。
Cytokine. 2024 Aug;180:156653. doi: 10.1016/j.cyto.2024.156653. Epub 2024 May 22.
8
Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.与秘鲁 COVID-19 住院患者预后较差相关的细胞因子谱。
Front Immunol. 2021 Sep 1;12:700921. doi: 10.3389/fimmu.2021.700921. eCollection 2021.
9
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19.细胞因子风暴的特征反映了 COVID-19 中的过度炎症性内皮功能障碍。
J Allergy Clin Immunol. 2021 Jan;147(1):107-111. doi: 10.1016/j.jaci.2020.08.031. Epub 2020 Sep 10.
10
Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers.利用与疾病相关的血液生物标志物区分 COVID-19 与炎症诱导的细胞因子风暴综合征。
Arthritis Rheumatol. 2021 Oct;73(10):1791-1799. doi: 10.1002/art.41763. Epub 2021 Sep 3.

引用本文的文献

1
Advances in understanding the role of pentraxin-3 in lung infections.了解五聚素3在肺部感染中作用的研究进展。
Front Immunol. 2025 Apr 17;16:1575968. doi: 10.3389/fimmu.2025.1575968. eCollection 2025.
2
Different dynamics of soluble inflammatory mediators after clearance of respiratory SARS-CoV-2 versus blood-borne hepatitis C virus infections.清除呼吸道 SARS-CoV-2 与血源性丙型肝炎病毒感染后可溶性炎症介质的不同动力学。
Sci Rep. 2024 Nov 22;14(1):29013. doi: 10.1038/s41598-024-79909-8.

本文引用的文献

1
Daily disease severity in patients with COVID-19 admitted to the hospital: The SCODA (severity of coronavirus disease assessment) score.每日 COVID-19 住院患者疾病严重程度:SCODA(冠状病毒疾病严重程度评估)评分。
PLoS One. 2023 Sep 8;18(9):e0291212. doi: 10.1371/journal.pone.0291212. eCollection 2023.
2
Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in COVID-19 patients.地塞米松可减轻 COVID-19 患者的干扰素相关细胞因子高反应性。
Front Immunol. 2023 Aug 8;14:1233318. doi: 10.3389/fimmu.2023.1233318. eCollection 2023.
3
Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
基于基线可溶性尿激酶型纤溶酶原激活物受体血浆水平指导的 COVID-19 住院患者使用阿那白滞素:一项真实世界、回顾性队列研究。
PLoS One. 2023 Apr 4;18(4):e0273202. doi: 10.1371/journal.pone.0273202. eCollection 2023.
4
Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia.靶向血浆蛋白质组学揭示了区分 COVID-19 与肺炎性脓毒症的特征。
Respir Res. 2023 Feb 24;24(1):62. doi: 10.1186/s12931-023-02364-y.
5
Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more.单剂量托珠单抗治疗新冠病毒疾病相关细胞因子风暴综合征:少即是多。
Br J Clin Pharmacol. 2025 Apr;91(4):938-946. doi: 10.1111/bcp.15690. Epub 2023 Feb 24.
6
A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.比较不同剂量托珠单抗和沙利鲁单抗治疗重症 COVID-19 的疗效:由于药物短缺的自然实验。
Int J Infect Dis. 2023 Apr;129:57-62. doi: 10.1016/j.ijid.2023.01.041. Epub 2023 Feb 2.
7
Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.基于宿主生物标志物的结核病和新冠肺炎检测及治疗监测定量快速检测方法。
iScience. 2023 Jan 20;26(1):105873. doi: 10.1016/j.isci.2022.105873. Epub 2022 Dec 26.
8
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.REMAP-CAP 随机临床试验中 COVID-19 危重症患者的长期(180 天)结局。
JAMA. 2023 Jan 3;329(1):39-51. doi: 10.1001/jama.2022.23257.
9
Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral Clearance.住院 COVID-19 患者病毒清除的免疫决定因素:循环中幼稚 CD4+T 细胞计数减少与病毒清除延迟相对应。
Cells. 2022 Sep 2;11(17):2743. doi: 10.3390/cells11172743.
10
Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19.免疫球蛋白 G1 Fc 糖基化作为严重 COVID-19 的早期标志。
EBioMedicine. 2022 Apr;78:103957. doi: 10.1016/j.ebiom.2022.103957. Epub 2022 Mar 22.